Printer Friendly

VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN GREECE

 SAN DIMAS, Calif., June 15 /PRNewswire/ -- Vestar, Inc. (NASDAQ: VSTR) today announced that AmBisome(R), the company's liposomal formulation of amphotericin B, has received full marketing approval in Greece, as a treatment for systemic fungal infections. Greece is the eighth country to grant full marketing approval for AmBisome, following rapidly on the approval granted in The Netherlands last week. The commercial launch of the product in Greece is expected to begin immediately.
 "We are extremely proud of the fact that our recent round of regulatory filings for AmBisome is meeting with such rapid and clear-cut success," said Roger J. Crossley, M.D., chairman, CEO and president of Vestar. "With each approval, we see AmBisome gaining further physician acceptance as a major medical resource for saving the lives of those with serious fungal infections."
 Vestar management noted that to date in 1993, The Netherlands and Greece have approved AmBisome. The product received full marketing approval in six countries during late 1991 and 1992: Ireland, Mexico, the United Kingdom, Sweden, Germany and Portugal.
 AmBisome is Vestar's trade name for its proprietary intravenous liposomal formulation of amphotericin B, the most commonly used drug for severe systemic fungal infections. The use of conventional amphotericin B has been severely limited by its serious toxicity at doses that are only marginally effective. In contrast, clinical data have demonstrated that AmBisome is well tolerated, permitting higher daily and cumulative doses than are considered safe for the conventional drug.
 Systemic fungal infections are serious infections with a mortality rate of up to 70 percent, that often occur in cancer patients treated with chemotherapy, particularly those with leukemia, as well as organ and bone marrow transplant patients, and AIDS patients. In clinical trials of AmBisome to date, 85 percent of patients have shown clinical improvement against a variety of fungal infections, with minimal side effects. With this positive safety and efficacy profile for AmBisome, Phase III, and IV trials are underway with a view toward gaining approval for use of the drug earlier in the treatment process.
 Vestar, headquartered in San Dimas, Calif., develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. Since 1989, Vestar has been marketing AmBisome, a liposomal formulation of amphotericin B, in Europe to treat systemic fungal infections. DaunoXome(R), a liposomal formulation of the chemotherapeutic agent daunorubicin, is Vestar's second major product. MiKasome, a liposomal formulation of the antibiotic amikacin, is currently in preclinical trials for potential use against drug- resistant tuberculosis. Among the company's proprietary drug delivery technologies are liposomes to encapsulate pharmaceuticals, and lipid prodrug technology for the development of orally active compounds.
 -0- 6/15/93
 /CONTACT: Michael E. Hart, chief financial officer, Vestar, Inc., 909-394-4119; Marcia A. Kean, executive vice president, or Chris Taylor, account executive, for Feinstein Partners Inc., 617-577-8110, for Vestar/
 (VSTR)


CO: Vestar, Inc. ST: California IN: MTC SU:

DJ -- NE007 -- 2151 06/15/93 13:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1993
Words:487
Previous Article:OEC, DIGITAL EQUIPMENT TO DEVELOP NEW CORBA-COMPLIANT TOOLKIT NEW PRODUCT OFFERS FASTER, EASIER, APPLICATION DEVELOPMENT
Next Article:AMERICAN EXPLORATION ANNOUNCES SALE OF CANADIAN CONQUEST SUBSIDIARY
Topics:


Related Articles
VESTAR'S AMBISOME(R) GAINS MARKETING APPROVAL IN THE UNITED KINGDOM
VESTAR'S AMBISOME GAINS MARKETING AND REIMBURSEMENT APPROVAL IN SWEDEN
VESTAR TO EXPAND PRODUCTION FACILITIES; SIGNS LEASE FOR 51,000-SQUARE-FOOT FACILITY
VESTAR TO EXPAND PRODUCTION FACILITIES; SIGNS LEASE FOR 51,000-SQUARE-FOOT FACILITY
VESTAR'S AMBISOME(R) GAINS MARKETING APPROVAL IN GERMANY
VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN PORTUGAL
FUJISAWA USA FILES IND APPLICATION FOR VESTAR'S AMBISOME(R)
VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN THE NETHERLANDS
VESTAR REPORTS SECOND QUARTER 1993 RESULTS; REVENUES UP 34 PERCENT AS R&D AND MARKETING EXPENDITURES ACCELERATE
VESTAR GRANTED REGULATORY APPROVAL IN SWEDEN FOR AMBISOME(R) PRODUCT ENHANCEMENTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters